Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on Monday, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also divested ALXN1101 to a newly formed subsidiary of BridgeBio Pharma LLC (Palo Alto, Calif.).